Transforming growth factor-β in cancer and metastasis
Top Cited Papers
Open Access
- 2 September 2006
- journal article
- review article
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 25 (3), 435-457
- https://doi.org/10.1007/s10555-006-9006-2
Abstract
Transforming growth factor-beta (TGF-β) is a multifunctional regulatory polypeptide that is the prototypical member of a large family of cytokines that controls many aspects of cellular function, including cellular proliferation, differentiation, migration, apoptosis, adhesion, angiogenesis, immune surveillance, and survival. The actions of TGF-β are dependent on several factors including cell type, growth conditions, and the presence of other polypeptide growth factors. One of the biological effects of TGF-β is the inhibition of proliferation of most normal epithelial cells using an autocrine mechanism of action, and this suggests a tumor suppressor role for TGF-β. Loss of autocrine TGF-β activity and/or responsiveness to exogenous TGF-β appears to provide some epithelial cells with a growth advantage leading to malignant progression. This suggests a pro-oncogenic role for TGF-β in addition to its tumor suppressor role. During the early phase of epithelial tumorigenesis, TGF-β inhibits primary tumor development and growth by inducing cell cycle arrest and apoptosis. In late stages of tumor progression when tumor cells become resistant to growth inhibition by TGF-β due to inactivation of the TGF-β signaling pathway or aberrant regulation of the cell cycle, the role of TGF-β becomes one of tumor promotion. Resistance to TGF-β-mediated inhibition of proliferation is frequently observed in multiple human cancers, as are various alterations in the complex TGF-β signaling and cell cycle pathways. TGF-β can exert effects on tumor and stromal cells as well as alter the responsiveness of tumor cells to TGF-β to stimulate invasion, angiogenesis, and metastasis, and to inhibit immune surveillance. Because of the dual role of TGF-β as a tumor suppressor and pro-oncogenic factor, members of the TGF-β signaling pathway are being considered as predictive biomarkers for progressive tumorigenesis, as well as molecular targets for prevention and treatment of cancer and metastasis.Keywords
This publication has 168 references indexed in Scilit:
- Signaling and Endocytosis: A Team Effort for Cell MigrationDevelopmental Cell, 2005
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- A role for Id in the regulation of TGF-β-induced epithelial–mesenchymal transdifferentiationCell Death & Differentiation, 2004
- Smad4/DPC4-dependent Regulation of Biglycan Gene Expression by Transforming Growth Factor-β in Pancreatic Tumor CellsPublished by Elsevier ,2002
- Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomasOncogene, 2000
- The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancerOncogene, 1999
- Overexpression of transforming growth factor ?-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cellsInternational Journal of Cancer, 1999
- Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma developmentOncogene, 1998
- The somatic mutation frequency of the transforming growth factor β receptor type II gene varies widely among different cancers with microsatellite instabilityEuropean Journal of Surgical Oncology, 1996
- Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory diseaseNature, 1992